ArticleRegenerative therapy2021
MiRNA-218 inhibits cell proliferation, migration and invasion by targeting Runt-related transcription factor 2 (Runx2) in human osteosarcoma cells.
Article in Regenerative therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Canine soft tissue sarcomas: the expression of RUNX2 and karyopherin alpha-2 in extraskeletal (soft tissues) and skeletal osteosarcomas.Frontiers in veterinary science · 2024Article
- Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.International journal of molecular sciences · 2023Review
- RUNX2 and Cancer.International journal of molecular sciences · 2023Review
- Bioinformatics analysis of lncRNAs in the occurrence and development of osteosarcoma.Translational pediatrics · 2022Article
- Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe deregulation of miRNA-218 has been found in a number of cancers. Using miRNA-218 as a target for Runt-related transcription factor 2 (Runx2), we sought to understand the role of miRNA-218 in osteosarcoma (OS).
methodsThe expression of miRNA-218 was detected in the OS tumor tissues and OS cells. The Runx2 expression level was evaluated in Saos-2, 143B, U2OS, and MG-63. miRNA-218 overexpressed U2OS cells were achieved by transfection with miRNA-218 mimics. The role of miRNA-218 in inhibiting OS tumorigenesis was explored by CCK8, colony formation, cell wound scratch and Transwell assay. TargetScan and dual-luciferase reporter assay identified the interaction between miRNA-218 and Runx2. The inhibitive effect of miRNA-218 on OS through targeting Runx2 was also evaluated.
resultsMiRNA-218 levels were remarkably down-regulated in OS tumor tissues and cell lines. The overexpression of miRNA-218 suppressed U2OS cell development and metastasis. The target interaction between miRNA-218 and Runx2 was validated, and their expression showed a negative correlation in U2OS cells. The suppressed U2OS cell development and metastasis were remarkably reversed by Runx2 overexpression.
conclusionMiRNA-218 showed an inhibitive effect on the development and metastasis of osteosarcoma cell proliferation by targeting Runx2. Our findings may provide novel clues for OS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.